SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

(2018) Ming Li et al.   BMC CANCER

lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer

(2018) Zehua Wang et al.   CANCER CELL

SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival

(2018) J. Y. Liu et al.   ONCOGENE

Overexpression of MYC binding protein promotes invasion and migration in gastric cancer

(2018) Lijie Gong et al.   Oncology Letters

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer

(2018) Irina Tsibulak et al.   BRITISH JOURNAL OF CANCER

SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma

(2018) Yu-Feng Yang et al.   Molecular Cancer

An intrinsic S/G2 checkpoint enforced by ATR

(2018) Joshua C. Saldivar et al.   SCIENCE

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

Astrin-SKAP complex reconstitution reveals its kinetochore interaction with microtubule-bound Ndc80

(2017) David M Kern et al.   eLife

Immunotherapy and tumor microenvironment

(2016) Haidong Tang et al.   CANCER LETTERS

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

miR-539 inhibits prostate cancer progression by directly targeting SPAG5

(2016) Hongtuan Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis

(2016) Tarek M A Abdel-Fatah et al.   LANCET ONCOLOGY

Biology and Management of Patients With Triple-Negative Breast Cancer

(2016) P. Sharma   ONCOLOGIST

miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia

(2016) Xi Jiang et al.   Nature Communications

Triple-negative Breast Carcinoma

(2015) Shikha Bose   ADVANCES IN ANATOMIC PATHOLOGY

Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer

(2015) Axel Muendlein et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Erratum: SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway

(2015) L-J Yuan et al.   Cell Death & Disease

Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex

(2015) Martin Fischer et al.   Oncotarget

Distribution ofBRCA1andBRCA2Mutations in Asian Patients with Breast Cancer

(2014) Haeyoung Kim et al.   Journal of Breast Cancer

The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks

(2014) M. Tahara et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of mTORC1 by Astrin and Stress Granules Prevents Apoptosis in Cancer Cells

(2013) Kathrin Thedieck et al.   CELL

Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein

(2010) J Xiong et al.   ONCOGENE

MYC in breast tumor progression

(2008) Yinghua Chen et al.   Expert Review of Anticancer Therapy